Is the business good?
How good a business is NGVT?
Ingevity Corporation keeps −11% of every revenue dollar as profit after everything, against 5.2% for the median Specialty Chemicals name.
−11%
Net margin · Specialty Chemicals median 5.2% · 12 months to Q1 2026
- Share count, year on year
- −1.8%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 2.4%
R&D as % of revenue
- Gross margin
- 39%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 33% |
| FY2021 | 30% |
| FY2022 | 27% |
| FY2023 | 35% |
| FY2024 | 35% |
| FY2025 | 36% |
Details›
- Gross margin12 months to Q1 2026
- 39%
- Net margin12 months to Q1 2026
- −11%
- Free cash flow margin
- 20%
- R&D as % of revenue
- 2.4%
- Revenue, trailing twelve months
- $1.21B
- Free cash flow, trailing twelve months
- $246M
- Net income, trailing twelve months
- −$128M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Specialty Chemicals
Ranks #7 of 36 by Smart Score